Preventive substrate ablation in chronic post-myocardial infarction patients with high-risk scar characteristics for ventricular arrhythmias: rationale and design of PREVENT-VT study
Authors:
- 13 October 2022
- journal article
- research article
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 66 (1) , 39-47
Abstract
Background Recent studies showed that an early strategy for ventricular tachycardia (VT) ablation resulted in reduction of VT episodes or mortality. Cardiac magnetic resonance (CMR)-derived border zone channel (BZC) mass has proved to be a strong non-invasive predictor of VT in post-myocardial infarction (MI). CMR-guided VT substrate ablation proved to be safe and effective for reducing sudden cardiac death (SCD) and VA occurrence. Methods PREVENT-VT is a prospective, randomized, multicenter, and controlled trial designed to evaluate the safety and efficacy of prophylactic CMR-guided VT substrate ablation in chronic post-MI patients with CMR-derived arrhythmogenic scar characteristics. Chronic post-MI patients with late gadolinium enhancement (LGE) CMR will be evaluated. CMR images will be post-processed and the BZC mass measured: patients with a BZC mass > 5.15 g will be eligible. Consecutive patients will be enrolled at 3 centers and randomized on a 1:1 basis to undergo a VT substrate ablation (ABLATE arm) or optimal medical treatment (OMT arm). Primary prevention ICD will be implanted following guideline recommendations, while non-ICD candidates will be implanted with an implantable cardiac monitor (ICM). The primary endpoint is a composite outcome of sudden cardiac death (SCD) or sustained monomorphic VT, either treated by an ICD or documented with ICM. Secondary endpoints are procedural safety and efficiency outcomes of CMR-guided ablation. Discussion In some patients, the first VA episode causes SCD or severe neurological damage. The aim of the PREVENT-VT is to evaluate whether primary preventive substrate ablation may be a safe and effective prophylactic therapy for reducing SCD and VA occurrence in patients with previous MI and high-risk scar characteristics based on CMR. Trial registration ClinicalTrials.gov, NCT04675073, registered on January 1, 2021.Keywords
This publication has 29 references indexed in Scilit:
- Primary Prevention of Sudden Cardiac Death in a Nonischemic Dilated Cardiomyopathy PopulationCirculation: Arrhythmia and Electrophysiology, 2013
- Three-Dimensional Architecture of Scar and Conducting Channels Based on High Resolution ce-CMRCirculation: Arrhythmia and Electrophysiology, 2013
- Assessment of Myocardial Scarring Improves Risk Stratification in Patients Evaluated for Cardiac Defibrillator ImplantationJACC, 2012
- Extent of and Reasons for Nonuse of Implantable Cardioverter Defibrillator Devices in Clinical Practice Among Eligible Patients With Left Ventricular Systolic DysfunctionCirculation: Cardiovascular Quality and Outcomes, 2011
- Noninvasive Identification of Ventricular Tachycardia-Related Conducting Channels Using Contrast-Enhanced Magnetic Resonance Imaging in Patients With Chronic Myocardial InfarctionJACC, 2011
- Prognostic Importance of Defibrillator Shocks in Patients with Heart FailureNew England Journal of Medicine, 2008
- Prophylactic Catheter Ablation for the Prevention of Defibrillator TherapyNew England Journal of Medicine, 2007
- Infarct Tissue Heterogeneity by Magnetic Resonance Imaging Identifies Enhanced Cardiac Arrhythmia Susceptibility in Patients With Left Ventricular DysfunctionCirculation, 2007
- Sudden Cardiac Death Unresponsive to Implantable Defibrillator Therapy: An Urgent Target for Clinicians, Industry and GovernmentJournal of Interventional Cardiac Electrophysiology, 2005
- Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation.Circulation, 1988